TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05857657

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: : lower leg kinesiotaping
Description: Kinesiotaping will be applied on tibialis anterior for 30 minutes for one session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: propriocepticve neuromuscular facilitation
Description: :Proprioceptive neuromuscular facilitation hold relax technique will be applied to ankle with 15-30 repititions on affected side for one session

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: propriocepticve neuromuscular facilitation with lower leg kinesiotaping
Description: Kinesiotaping will be applied on tibialis anterior for 30 minutes with proprioceptive neuromuscular facilitation hold relax technique will be applied to ankle with 15-30 repititions on affected side for one session
Study: NCT04715984

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurophysiology recordings
Description: Neurophysiology recordings will be performed during deep brain stimulation surgery and their relationship to performance on a working memory task evaluated

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neural stimulation
Description: Neural stimulation will be delivered during a working memory task and its impact on task performance quantified
Study: NCT06358859

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food is Medicine
Description: Regularly distributed fruit and vegetable produce boxes and nutrition education materials.
Study: NCT06523400

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mexiletine granules for prolonged-release oral suspension
Description: Mexiletine PR

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT05345418

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical Cord-Derived Mesenchymal Stem Cell for Male Patients with Sexual Deficiency
Description: Patients will receive two administrations at a dose of 1.5 million cells/kg patient bodyweight via the IV route with a 3-month intervening interval. A validated umbilical cord blood mesenchymal stem cells (UC-MSC) line was selected from the Vinmec Tissue Bank and cultured under xeno-free, serum-free and antibiotic-free conditions as previously described. To prepare UC-MSCs for therapy, aliquots of Passage 3 (P3) UC-MSCs will be thawed and cultured to P5 to get approximately 500 million cells and dispensed to 10 million UC-MSCs/ml/vial for cryopreservation. Upon request from the clinical team, aliquots of P5 UC-MSCs will be thawed in a temperature control water bath or incubator on the infusion day. The UC-MSCs will be washed and suspended in Ringer Lactate.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord-Derived Mesenchymal Stem Cell for Male Patients with Sexual Deficiency
Description: Patients will receive two administrations at a dose of 1.5 million cells/kg patient bodyweight via the IV route with a 3-month intervening interval. A validated umbilical cord blood mesenchymal stem cells (UC-MSC) line was selected from the Vinmec Tissue Bank and cultured under xeno-free, serum-free and antibiotic-free conditions as previously described. To prepare UC-MSCs for therapy, aliquots of Passage 3 (P3) UC-MSCs will be thawed and cultured to P5 to get approximately 500 million cells and dispensed to 10 million UC-MSCs/ml/vial for cryopreservation. Upon request from the clinical team, aliquots of P5 UC-MSCs will be thawed in a temperature control water bath or incubator on the infusion day. The UC-MSCs will be washed and suspended in Ringer Lactate.
Study: NCT04884516

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Retinol gummy
Description: Participants take one retinol gummy per day
Study: NCT05619484

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart AFO
Description: Diagnostic ankle-foot orthosis with AFO stiffness and range of motion settings adjusted using a mobile application
Study: NCT05010174

Intervention type: DRUG
Intervention: MDR product
Description: Observation of patients previously receiving MDR product(s)
Study: NCT04795414

Intervention type: BIOLOGICAL
Intervention: SARS-CoV-2 Vaccine(Vero Cell), Inactivated
Description: The subjects of Vaccination Group will receive two doses, 21 days apart of inactivated SARS-CoV-2 vaccine (4 μg of BBIBP-CorV)
Study: NCT06080620

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified radical mastectomy for breast cancer
Description: Modified radical mastectomy for breast cancer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified radical mastectomy for breast cancer
Description: Modified radical mastectomy for breast cancer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant therapy
Description: neoadjuvant chemotherapy（Drugs： DoxorubicinPaclitaxelAlbumin paclitaxelCyclophosphamide）, endocrine therapy（Drugs：ToremifenZoladexAromatase inhibitors）, targeted therapy（Drugs：trastuzumabPertuzumab）

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Systematic treatment
Description: chemotherapyDrugs： DoxorubicinPaclitaxelAlbumin paclitaxelCyclophosphamide）, endocrine therapy（Drugs：ToremifenZoladexAromatase inhibitors）, targeted therapy（Drugs：trastuzumabPertuzumab），radiotherapy（Yikeda Versa HD linear acceleratorVarian Trilogy linear accelerator）

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Systematic treatment
Description: chemotherapyDrugs： DoxorubicinPaclitaxelAlbumin paclitaxelCyclophosphamide）, endocrine therapy（Drugs：ToremifenZoladexAromatase inhibitors）, targeted therapy（Drugs：trastuzumabPertuzumab），radiotherapy（Yikeda Versa HD linear acceleratorVarian Trilogy linear accelerator）
Study: NCT06504030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modified-DEP
Description: For non-EBV-HLH patients: Liposomes doxorubicin, 25 mg/m2 d1, etoposide 100 mg/m2 d1, methylprednisolone 1 mg/kg d1-3, then tapering according to patients condition, fully stop with d7 to d10; ruxolitinib, 15 mg bid. Emapalumab, if needed.~For EBV-HLH patients: PD-1 monoclonal antibody, 2 mg/kg (maximum dose, 200 mg) d-3, liposomes doxorubicin, 25 mg/m2 d1, etoposide 100 mg/m2 d1, methylprednisolone 1 mg/kg d1-3, then tapering according to patients condition, fully stop with d7 to d10; ruxolitinib, 15 mg bid. Emapalumab, if needed.
Study: NCT06193538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant NV-A01 adenovirus injection
Description: Patients with advanced glioblastoma were intratumoral injected with NV-A01. Or the NV-A01 was injected after tumor resection.
Study: NCT04772092

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: during the routine blood test, collection of additional blood samples:~* 1 x 5 mL heparinized tube for plasma collection and storage~* 1 heparinized 5 mL tube for immunophenotyping~* 4 x 10 mL EDTA tubes for white blood cell (WBC) collection and cryopreservation

Intervention type: OTHER
Intervention: Data collection
Description: * clinical examination data~* test results to measure the degree of geriatric fatigability~* Frailty screening questionnaire for neoplasia patients (G8 score)
Study: NCT06468644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemoradiotherapy （CRT）+sintilimab 1
Description: radiotherapy (50.4Gy/1.8Gy/28f)+chemotherapy (paclitaxel 150mg/m2 D1+cisplatin 25mg/m2 D1-3，Q3W)+Sintilimab (200mg, iv, D1, Q3W) Consolidation therapy: Sintilimab: 200mg, iv, D1, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRT+sintilimab 2
Description: radiotherapy (60Gy/2Gy/30f)+chemotherapy (paclitaxel 150mg/m2 D1+cisplatin 25mg/m2 D1-3，Q3W)+Sintilimab (200mg, iv, D1, Q3W) Consolidation therapy: Sintilimab: 200mg, iv, D1, Q3W
Study: NCT04926753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil, Cisplatin, Toripalimab
Description: Drug: FP combined with Toripalimab Combination drugs: 5-Fluorouracil(F), Cisplatin/Carboplatin(P) and Toripalimab every 21 days for 2 cycles This is a single-arm study with all patients receiving these three drugs.
Study: NCT05295173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of recombinant human tissue plasminogen kinase derivatives
Description: 18mg/10ml/stick, provided by Angde Biotech

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human tissue plasminogen activator
Description: 20mg/stick, 50mg/stick, provided by Shanghai Boehringer Ingelheim Pharmaceutical Co. Ltd.
Study: NCT04374474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olfactory retraining
Description: Olfactory retraining Olfactory training is performed by exposing patients twice daily to essential oils with four specific odors, present in glass jars with soaked cotton pads: phenyl ethyl alcohol, rose; eucalyptol, eucalyptus; citronellal, lemon; eugenol, cloves.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olfactory retraining
Description: Olfactory retraining Olfactory training is performed by exposing patients twice daily to essential oils with four specific odors, present in glass jars with soaked cotton pads: phenyl ethyl alcohol, rose; eucalyptol, eucalyptus; citronellal, lemon; eugenol, cloves.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroid nasal irrigation
Description: Nasal irrigation with corticosteroid (budesonide) consists of 240-mL nasal irrigation with Pulmicort Respules (0.5mg) across both nose sides via NeilMed Sinus Rinse bottle (Santa Rosa, California, USA).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: smell household Items
Description: Participants will receive a paper hand-out about post-viral anosmia with instructions to smell common household items

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Nasal Irrigation
Description: Participants from all three groups will use nasal rinse (NeilMed Sinus Rinse) two times a day.
Study: NCT06565585

Intervention type: PROCEDURE
Intervention: Glans-sparing surgery
Description: Patients who underwent glans-sparing surgery
Study: NCT04374474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasal Irrigation
Description: Participants from all three groups will use nasal rinse (NeilMed Sinus Rinse) two times a day.
Study: NCT06694766

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample collection
Description: A blood sample collection of 18.5 mL will be required for the immunogenicity component.
Study: NCT05054621

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heterologous prime-boost schedule with AZD1222 and MVC-COV1901
Description: Participants will be divided into two subgroups according to the intervals, 28-42 days and 56-70 days, between the prime and booster doses.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Homologous prime-boost schedule with two doses of AZD1222
Description: Participants will be divided into two subgroups according to the intervals, 28-42 days and 56-70 days, between the prime and booster doses.
Study: NCT05923333

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: B. infantis Rosell®-33
Description: B. infantis Rosell®-33 + maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study: NCT04954625

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Blood Patch
Description: All patients will be assessed on the morning of postoperative Day 3 and 4 for the presence of an air leak. If an air leak is present, 60-100 ml of autologous blood will be drawn from a peripheral vein and immediately instilled into the chest tube. The individual who draws blood is that the discretion of the site principal investigator. The tubing will be elevated over an IV pole while the patient remains in bed, moving position every 15 minutes for 1 hour to distribute the blood throughout the pleural cavity. The tubing support will then be removed, allowing the chest tube to drain. After ABP intervention, the chest tube will remain to water seal, as long as the patient tolerates it.
Study: NCT04841564

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound approach of serratus anterior block
Description: After induction of general anesthesia, the ultrasound probe will be placed longitudinally oblique just below the mid-clavicle. After identifying the second rib, the probe will be moved caudally and laterally (obliquely), towards the mid-axillary line to identify the 3rd, 4th and 5th ribs.. The fascial plane between the serratus anterior muscle and latissimus dorsi muscle will be identified over the 4th rib in the mid-axillary region. The block will be performed with a needle (22-G, 50-mm) introduced in-plane to enter deep to the serratus anterior muscle, and 30 ml 0.25 bupivacaine will be injected.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open approach of serratus anterior block
Description: After resection of the breast and identification of the serratus anterior muscle, the surgeon will be asked to palpate the ribs below the clavicle and localize the fourth rib. A 22-G, 50-mm needle will be introduced deep to the serratus anterior muscle contacting the rib, and 30 ml 0.25 bupivacaine will be injected.
Study: NCT05737641

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: water ingestion
Description: ingestion of water after an 8h-fasting period

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: jelly ingestion
Description: ingestion of jelly after an 8h-fasting period
Study: NCT05592886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMT04 formula
Description: The SMT04 formula is a synbiotic containing probiotics and prebiotics

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Active placebo
Description: The active placebo is 2 mg Vitamin C with an inert substance made of starch filler. The flavor, coloring and appearance are unidentifiable to the study product.
Study: NCT04731441

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Exercise Program Prior to CRS-HIPEC
Description: Exercise Program Subjects randomized to the intervention arm should have 6 weeks of home exercise prior to surgery, with a minimum of 5 weeks and not more than 7 weeks. The program will begin with an exercise consultation appointment with a certified fitness professional. During this consultation participants will receive an exercise manual for individualized home-based exercise and a practical introduction by an exercise and cancer specialist. PowerBlock adjustable dumbbells will be used for resistance training exercises and walking or jogging will be the primary type of aerobic training. The current program design was developed and successfully used with women with breast cancer. Thus, some components may need modification for this group of patients with advanced GI cancer.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Education
Description: Control arm: Subjects randomized to the control arm will receive education and a handbook on the benefits of exercise and will be encouraged to have adequate protein in their diet and provided with the list of high protein foods and nutritional information. These subjects will undergo the same assessments as the intervention arm at all time points. Control subjects will be offered a 6-week home exercise program 3 months after CRS/HIPEC, as described in sections 7.2.1-7.2.3. Results and outcomes will not be recorded.
Study: NCT05478174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Description: HSK3486 for induction of general anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol for induction of general anesthesia.
Study: NCT06444477

Intervention type: OTHER
Intervention: ITP and cancer
Description: ITP and cancer
Study: NCT04954625

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (per Physician)
Description: Patients randomized to Standard of Care will be treated as their surgeon would as routine. This may mean postoperative observation, of another type of intervention.
Study: NCT06149624

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: upfront advice to walk
Description: Control participants will be given upfront advice to walk and also given the wearable activity monitor (Fitbit) and asked to record the total steps achieved each day in a provided log book.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised exercise
Description: The onsite physiotherapist will also be trained in appropriate supervision and monitoring of exercise therapy in participants with HIV. This training will include titration of the exercise prescription to ensure safe progress is achieved. Participants will be scheduled to come to Mildmay 2 times per week for eight weeks to perform treadmill walking exercise. Intensity will be regulated using 40-60% of heart rate reserve. Additionally, ratings of perceived exertion via the Adult OMNI Walk/Run Scale will be used to guide the intensity of exercise subjectively at a moderate level. The exercise dose participants complete are standard prescriptions for participants with HIV, according to the American College of Sports Medicine.19 The physiotherapist will document the total steps achieved, including the supervised treadmill sessions and activity completed outside the supervised exercise setting (provided by participants via a log book).
Study: NCT05081323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-applied treatment for phobias
Description: The proposed treatment consists of four stages that use different visual elements to represent and replace a real rat in a gradual exposure treatment for specific phobia for animals. With the order of the stages, the intensity of the phobic stimulus increases. In each stage the participant is gradually exposed to a certain amount of elements that represent a phobic situation or object. Graduality considers an approach with realism, interaction, and intensity. The treatment also includes a virtual therapeutic assistant that guides, provides information, and tries to reduce any alteration captured by the participant's heart rate monitoring through deep breathing exercises.
Study: NCT05839665

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Humidified high-flow nasal oxygen
Description: Humidified high-flow oxygen delivered via the Optiflow device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard nasal cannula
Description: Oxygen delivered with high flows via a standard nasal cannula

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Facemask
Description: Oxygen delivered with facemask
Study: NCT06437405

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vinegar liquid
Description: one pill daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vinegar pill
Description: One pill daily
Study: NCT05644327

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiovascular training (CT)
Description: 12 weeks of CT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Description: 12 weeks of RT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal training (MT)
Description: 12 weeks of MT
Study: NCT04939623

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Probenecid
Description: The Investigators aim to recruit 40 participants who will be followed for 12 weeks in duration. Participants will be randomized in a 2:2:1 ratio to one of probenecid 500 mg, 1000 mg, or placebo PO BID for 12 weeks. Justification for use of a non-active placebo comparator includes the fact that this trial is meant to identify tolerability and safety of probenecid in a population of patients living with chronic pain, this will be best measured by comparing to a non-active placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probenecid
Description: The Investigators aim to recruit 40 participants who will be followed for 12 weeks in duration. Participants will be randomized in a 2:2:1 ratio to one of probenecid 500 mg, 1000 mg, or placebo PO BID for 12 weeks. Justification for use of a non-active placebo comparator includes the fact that this trial is meant to identify tolerability and safety of probenecid in a population of patients living with chronic pain, this will be best measured by comparing to a non-active placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probenecid
Description: The Investigators aim to recruit 40 participants who will be followed for 12 weeks in duration. Participants will be randomized in a 2:2:1 ratio to one of probenecid 500 mg, 1000 mg, or placebo PO BID for 12 weeks. Justification for use of a non-active placebo comparator includes the fact that this trial is meant to identify tolerability and safety of probenecid in a population of patients living with chronic pain, this will be best measured by comparing to a non-active placebo.
Study: NCT06567665

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine
Description: Leucine is a dietary supplement that can be easily purchased over the counter at health food stores. It is an essential amino acid and is involved in stimulate muscle protein synthesis.
Study: NCT05357391

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Pressure Injury Prediction and Education model using a mobile application system
Description: Data from the medical records will be used to analyze the probability and risk of wound healing for creating a Pressure Injury Prediction and Education Model using a mobile application system.
Study: NCT06716970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QR12000 75mg
Description: QR12000 75mg QD
Study: NCT05915026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoquatrane (BAY1747846)
Description: 0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose
Study: NCT05268250

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: R2D2 mHealth intervention
Description: R2D2 mHealth treatment will use cognitive behavioral therapy, mindfulness, and behavioral activation strategies
Study: NCT06568471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lerodalcibep
Description: PCSK9 inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: placebo
Study: NCT06568614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYH2039
Description: SYH2039 dosed orally
Study: NCT05415618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage
Description: Manual lymphatic drainage will be applied 5 days a week for about 15 minutes every day for 4 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: splint
Description: In splint treatment, a volar-supported splint that keeps the wrist in a neutral position will be preferred and it will be recommended to both groups to be used only at night for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nerve gliding
Description: Median nerve gliding exercises as a home exercise program will be performed by the patient 5 days a week for 4 weeks. It will be performed in 6 different consecutive positions of the hand and wrist.